BioSig Technologies Second Quarter 2023 Earnings: US$0.16 loss per share (vs US$0.15 loss in 2Q 2022)
BioSig Technologies (NASDAQ:BSGM) Second Quarter 2023 Results
Key Financial Results
Net loss: US$11.1m (loss widened by 89% from 2Q 2022).
US$0.16 loss per share (further deteriorated from US$0.15 loss in 2Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BioSig Technologies Earnings Insights
Looking ahead, revenue is forecast to grow 92% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 15% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 5 warning signs for BioSig Technologies you should be aware of, and 2 of them shouldn't be ignored.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
